arrow
B

Benjamin Solomon

University of Melbourne
H指数:98
被引数:6.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sovereignty and Survival: Understanding Lung Cancer Outcomes for Aboriginal and Torres Strait Islander People in Australia, a Case–Control Study

主权与生存:澳大利亚原住民和托雷斯海峡岛民肺癌结局研究,一项病例对照研究

2026-09-210
OAAI
Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer in a Phase 2 Study

洛拉替尼在II期研究中对<em>ALK</em>阳性晚期非小细胞肺癌患者的最终生物标志物和疗效分析

2026-09-170
OAAI
Adjuvant alectinib versus chemotherapy in resected ALK- positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial

辅助阿来替尼与化疗在切除后的ALK阳性非小细胞肺癌(ALINA):一项随机、开放标签、III期试验的健康相关生活质量与安全性结果

2026-08-010
OAAI
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial

Reptrectinib治疗NTRK融合阳性的晚期实体瘤: 1/2期试验

2026-02-040
OA
Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with ALK-positive non-small cell lung cancer

ALINA研究结果的大众语言摘要:alectinib与化疗相比,在ALK阳性非小细胞肺癌患者术后的应用

2025-12-310
PRE
Evaluating CD103+ intratumoral immune cell abundance and PD-L1 CPS in primary tumors versus lymph nodes in Human papillomavirus associated oropharyngeal Cancer

评估人乳头状瘤病毒相关口咽癌中,原发肿瘤与淋巴结中CD103+肿瘤内免疫细胞丰度及PD-L1 CPS的差异。

2025-11-210
PRE
Brief Report: Alectinib with salvage platinum-taxane chemotherapy in a pregnant woman with ALK-rearranged NSCLC and rapid disease progression followed by a successful pregnancy

简报:在一例ALK重排非小细胞肺癌(NSCLC)且疾病快速进展的孕妇中,应用阿来替尼联合挽救性铂类-紫杉烷类化疗,并成功妊娠。

2025-11-200
PRE
Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer

编辑关注声明:同时靶向IGF-1R和ALK在ALK融合阳性肺癌中的合理性

2025-11-200
OAAI
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary
2025-03-010
OAAI
Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation-Positive NSCLC An Open-Label Phase 2 Trial (ILLUMINATE)

Durvalumab,Tremelimumab和铂类化疗在EGFR突变阳性NSCLC中的应用开放标签2期试验 (illumate)

2025-02-010
OA
Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis

高尔基体定位的环指蛋白121是MYCN驱动的神经母细胞瘤肿瘤发生所必需的

2024-10-140
OAAI